Clinical Trial Update: Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating stereotactic radiosurgery or local ablation followed by erlotinib in non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-01-12